DYADIC INTERNATIONAL INC
DYAINasdaq
$1.26
↑ +5.9%Jul 17 close · end-of-day
Price
1Y↑ +29.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$45.9M
Enterprise Value
$40.3M
P/E
—
P/S
12.0
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$3.8M
Net Income (TTM)
-$7.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-186.3%
Net Margin
-191.5%
ROE
1788.4%
ROIC
—
Debt / Equity
—
Net Cash
$5.6M
Return 1Y
+28.6%
Company profile
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.
- CEO
- Mark A. Emalfarb
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 7
- Headquarters
- Florida
- Website
- dyadic.com
Management & directors
- Emalfarb Mark ACEO
- Hazelton Joseph PPresident and COO
- Rawson Ping WangChief Financial Officer
- Tchelet RonenVP of Research and Bus. Dvlpmt
Roles derived from SEC Form 4 filings.
Earnings
DYAI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.1M↑ +182.3%
Diluted EPS-$0.05↓ -28.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | $2.4M | $2.9M | $2.9M | $3.5M | $3.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.0M | -$14.7M | -$10.2M | -$8.2M | -$5.9M | -$7.2M |
| Net income | -$9.3M | -$13.1M | -$9.7M | -$6.8M | -$5.8M | -$7.4M |
| Diluted EPS | — | — | — | — | -$0.20 | -$0.23 |
| Operating cash flow | -$6.6M | -$11.3M | -$8.1M | -$6.7M | -$4.0M | -$5.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -625.9% | -612.7% | -346.9% | -283.9% | -168.8% | -232.8% |
| Net margin | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -238.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $385,896.00 | $2.0M | $817,376.00 | $393,572.00 | $966,630.00 | $1.2M | $565,526.00 | $1.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.0M | -$202,614.00 | -$1.5M | -$2.0M | -$1.7M | -$1.9M | -$1.5M | -$1.9M |
| Net income | -$2.0M | -$203,460.00 | -$1.6M | -$2.0M | -$1.8M | -$2.0M | -$1.6M | -$2.0M |
| Diluted EPS | -$0.07 | -$0.01 | — | -$0.07 | -$0.06 | -$0.06 | -$0.04 | -$0.05 |
| Operating cash flow | -$2.0M | -$201,057.00 | -$696,395.00 | -$1.9M | -$130,015.00 | -$1.9M | -$1.8M | -$2.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -529.3% | -10.4% | -187.2% | -508.8% | -178.9% | -165.3% | -271.6% | -171.3% |
| Net margin | -530.0% | -10.4% | -189.7% | -515.2% | -185.6% | -169.7% | -277.1% | -175.9% |
Company news
Jul 16, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-02 | TCHELET RONEN· VP of Research and Bus. Dvlpmt | Award | 18,064 | $0.00 | $0.00 | filing |
| 2026-01-02 | Rawson Ping Wang· Chief Financial Officer | Award | 29,158 | $0.00 | $0.00 | filing |
| 2026-01-02 | Hazelton Joseph P· President & COO | Award | 36,418 | $0.00 | $0.00 | filing |
| 2026-01-02 | EMALFARB MARK A· CEO | Award | 102,609 | $0.00 | $0.00 | filing |
| 2026-01-02 | HERBST SETH | Option exercise | 21,552 | — | — | filing |
| 2026-01-02 | Lucy Patrick K. | Option exercise | 21,552 | — | — | filing |
| 2026-01-02 | Kaye Jack | Option exercise | 21,552 | — | — | filing |
| 2025-08-01 | Hazelton Joseph P· President and COO | Buy | 26,000 | $0.95 | $24,700.00 | filing |
| 2025-06-20 | Tarnok Michael P. | Option exercise | 10,776 | — | — | filing |
| 2025-06-20 | Bose Arindam | Option exercise | 10,776 | — | — | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.